Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Bought by Wealth Enhancement Advisory Services LLC

Wealth Enhancement Advisory Services LLC raised its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 11.6% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 23,151 shares of the biopharmaceutical company’s stock after purchasing an additional 2,412 shares during the quarter. Wealth Enhancement Advisory Services LLC’s holdings in Regeneron Pharmaceuticals were worth $22,283,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. West Paces Advisors Inc. raised its holdings in Regeneron Pharmaceuticals by 575.0% in the 1st quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 23 shares during the period. Fortitude Family Office LLC acquired a new position in Regeneron Pharmaceuticals in the 4th quarter worth about $31,000. MCF Advisors LLC raised its holdings in Regeneron Pharmaceuticals by 50.0% in the 4th quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 12 shares during the period. Criterion Capital Advisors LLC acquired a new position in Regeneron Pharmaceuticals in the 4th quarter worth about $37,000. Finally, Bruce G. Allen Investments LLC acquired a new position in Regeneron Pharmaceuticals in the 4th quarter worth about $40,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Analysts Set New Price Targets

REGN has been the subject of a number of analyst reports. StockNews.com cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Tuesday, April 30th. JPMorgan Chase & Co. upped their price target on Regeneron Pharmaceuticals from $1,050.00 to $1,150.00 and gave the company an “overweight” rating in a research report on Monday, June 17th. Royal Bank of Canada restated an “outperform” rating and issued a $1,229.00 price target on shares of Regeneron Pharmaceuticals in a research report on Monday. UBS Group upped their price target on Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the company a “buy” rating in a research report on Wednesday, April 17th. Finally, Argus upped their price target on Regeneron Pharmaceuticals from $1,060.00 to $1,170.00 and gave the company a “buy” rating in a research report on Tuesday. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $1,015.91.

Regeneron Pharmaceuticals Price Performance

Shares of REGN opened at $1,050.86 on Friday. The stock’s 50 day moving average is $978.05 and its two-hundred day moving average is $948.28. Regeneron Pharmaceuticals, Inc. has a twelve month low of $684.80 and a twelve month high of $1,081.17. The company has a current ratio of 5.27, a quick ratio of 4.51 and a debt-to-equity ratio of 0.10. The firm has a market capitalization of $115.79 billion, a PE ratio of 31.04, a P/E/G ratio of 2.21 and a beta of 0.13.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported $7.97 earnings per share (EPS) for the quarter, missing the consensus estimate of $8.46 by ($0.49). Regeneron Pharmaceuticals had a return on equity of 16.83% and a net margin of 29.45%. The company had revenue of $3.15 billion for the quarter, compared to analyst estimates of $3.19 billion. Research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.23 earnings per share for the current year.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, CEO Leonard S. Schleifer sold 25,000 shares of the business’s stock in a transaction on Tuesday, May 14th. The shares were sold at an average price of $979.25, for a total transaction of $24,481,250.00. Following the completion of the sale, the chief executive officer now directly owns 408,200 shares of the company’s stock, valued at approximately $399,729,850. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, CEO Leonard S. Schleifer sold 25,000 shares of the company’s stock in a transaction on Tuesday, May 14th. The shares were sold at an average price of $979.25, for a total transaction of $24,481,250.00. Following the completion of the sale, the chief executive officer now directly owns 408,200 shares of the company’s stock, valued at approximately $399,729,850. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Leonard S. Schleifer sold 22,830 shares of the company’s stock in a transaction on Friday, May 17th. The stock was sold at an average price of $979.23, for a total transaction of $22,355,820.90. Following the sale, the chief executive officer now directly owns 466,877 shares of the company’s stock, valued at $457,179,964.71. The disclosure for this sale can be found here. In the last three months, insiders sold 61,971 shares of company stock worth $61,217,654. Insiders own 7.48% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.